Search results
Results from the WOW.Com Content Network
Transitional cell carcinoma is a type of cancer that arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. [1] It typically occurs in the urothelium of the urinary system; in that case, it is also called urothelial carcinoma.
Bladder tumors are classified by their appearance under the microscope, and by their cell type of origin. Over 90% of bladder tumors arise from the cells that form the bladder's inner lining, called urothelial cells or transitional cells; the tumor is then classified as urothelial cancer or transitional cell cancer.
Invasive urothelial carcinoma is a type of transitional cell carcinoma. It is a type of cancer that develops in the urinary system: the kidney , urinary bladder , and accessory organs. Transitional cell carcinoma is the most common type of bladder cancer and cancer of the ureter , urethra , renal pelvis , the ureters , the bladder , and parts ...
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. [ 5 ] Common side effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite and swelling of the ...
Micrograph of a urethral cancer, urothelial cell carcinoma, found on a prostate core biopsy. ... Surgery is the most common treatment for cancer of the urethra. [8]
They cannot be reliably differentiated from low grade papillary urothelial carcinomas using cytology, [1] and their diagnosis (vis-a-vis low grade papillary urothelial carcinoma) has a poor inter-rater reliability. [2] Pathologic grading and staging tumors are: graded by the degree of cellular atypia (G1->G3), and staged: [citation needed ...
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]
In the United Statest, erdafitinib is indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.